T-Advisor, through its tool Market Opportunities, has detected the company Actelion, listed in the Swiss Exchange, as an opportunity for investment.
These are the main figures about performances and volatility in the last years:
The technical analysis reveals also more data:
The chart shows the evolution i the last year:
Finally, the risk analysis is as follows:
Actelion is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for diseases with significant unmet medical needs. Founded in 1997, it has more than 2,400 workers in over 30 countries. The company bought in 2006 CoTherix to enter the American market.
The revenues in 2013 increased a 4%, till CHF 1,784 million and the net income reached CHF 509 million, a 13% more. After a decreasing trend till 2012, the stock has begun to go up and has multiplied three times the price in the last two years.